Lirong Bao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lirong Bao has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Anqi Zhou
California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, USA
2 shared publications - Edwin Melencio Posadas
Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA
2 shared publications - Guangjuan Zheng
State Key Laboratory of Dampness Syndrome of Chinese Medicine The Second Clinical College of Guangzhou University of Chinese Medicine Guangzhou China
2 shared publications - Hsian-Rong Tseng
California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology
2 shared publications - Jiantong Dong
Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
2 shared publications - Meiping Zhao
Beijing National Laboratory for Molecular Sciences and MOE Key Laboratory of Bioorganic Chemistry and Molecular Engineering, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China
2 shared publications
Latest Publications
- Open Access
- 5 July 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (7) , eaav9186
Covalent chemistry on nanostructured substrates enables noninvasive quantification of gene rearrangements in circulating tumor cells
Dong et al . report gene rearrangement detection in circulating tumor cells by using covalent chemistry on nanosubstrates.
- 5 July 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (7) , eaav9186
Open AccessCovalent chemistry on nanostructured substrates enables noninvasive quantification of gene rearrangements in circulating tumor cells
Dong et al . report gene rearrangement detection in circulating tumor cells by using covalent chemistry on nanosubstrates.
- 20 March 2019
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 11 (15) , 13973-13983
Bio-Inspired NanoVilli Chips for Enhanced Capture of Tumor-Derived Extracellular Vesicles: Toward Non-Invasive Detection of Gene Alterations in Non-Small Cell Lung Cancer
Tumor-derived extracellular vesicles (EVs) present in bodily fluids are emerging liquid biopsy markers for non-invasive cancer diagnosis and treatment monitoring. Because the majority of EVs in circulation are not of tumor origin, it is critical to develop new platforms capable of enriching tumor-derived EVs from the blood. Herein, we introduce a biostructure-inspired NanoVilli Chip, capable of highly efficient and reproducible immunoaffinity capture of tumor-derived EVs from blood plasma samples. Anti-EpCAM-grafted silicon nanowire arrays were engineered to mimic the distinctive structures of intestinal microvilli, dramatically increasing surface area and enhancing tumor-derived EV capture. RNA in the captured EVs can be recovered for downstream molecular analyses by reverse transcription Droplet Digital PCR. We demonstrate that this assay can be applied to monitor the dynamic changes of ROS1 rearrangements and epidermal growth factor receptor T790M mutations that predict treatment responses and disease progression in non-small cell lung cancer patients.
- 20 March 2019
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 11 (15) , 13973-13983
Bio-Inspired NanoVilli Chips for Enhanced Capture of Tumor-Derived Extracellular Vesicles: Toward Non-Invasive Detection of Gene Alterations in Non-Small Cell Lung Cancer
Tumor-derived extracellular vesicles (EVs) present in bodily fluids are emerging liquid biopsy markers for non-invasive cancer diagnosis and treatment monitoring. Because the majority of EVs in circulation are not of tumor origin, it is critical to develop new platforms capable of enriching tumor-derived EVs from the blood. Herein, we introduce a biostructure-inspired NanoVilli Chip, capable of highly efficient and reproducible immunoaffinity capture of tumor-derived EVs from blood plasma samples. Anti-EpCAM-grafted silicon nanowire arrays were engineered to mimic the distinctive structures of intestinal microvilli, dramatically increasing surface area and enhancing tumor-derived EV capture. RNA in the captured EVs can be recovered for downstream molecular analyses by reverse transcription Droplet Digital PCR. We demonstrate that this assay can be applied to monitor the dynamic changes of ROS1 rearrangements and epidermal growth factor receptor T790M mutations that predict treatment responses and disease progression in non-small cell lung cancer patients.